Evidence map›Paper›PMID 33791710›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Dynamics Tracking.

Hui Chen, Zhao Li, Sheng Feng, Anni Wang, Melissa Richard-Greenblatt, Emily Hutson, Stefen Andrianus, Laurel J Glaser, Kyle G Rodino, Jianing Qian and 15 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Hui ChenDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Zhao LiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Sheng FengDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Anni WangBioengineering Graduate Program, University of Pennsylvania, Philadelphia, PA.
Melissa Richard-GreenblattDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Emily HutsonDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Stefen AndrianusDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Laurel J GlaserDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Kyle G RodinoDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Jianing QianDepartment of Computer and Information Science and GRASP Lab, University of Pennsylvania, Philadelphia, PA.
Dinesh JayaramanDepartment of Computer and Information Science and GRASP Lab, University of Pennsylvania, Philadelphia, PA.
Ronald G CollmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Abigail GlascockDepartment of Microbiology and Penn Center for Research on Coronavirus and Other Emerging Pathogens, University of Pennsylvania, Philadelphia, PA.
Frederic D BushmanDepartment of Microbiology and Penn Center for Research on Coronavirus and Other Emerging Pathogens, University of Pennsylvania, Philadelphia, PA.
Jae Seung LeeDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Sara CherryDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Alejandra FaustoDepartment of Microbiology and Penn Center for Research on Coronavirus and Other Emerging Pathogens, University of Pennsylvania, Philadelphia, PA.
Susan R WeissDepartment of Microbiology and Penn Center for Research on Coronavirus and Other Emerging Pathogens, University of Pennsylvania, Philadelphia, PA.
Hyun KooDepartment of Orthodontics, Divisions of Pediatric Dentistry and Community of Oral Health, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA.
Patricia M CorbyCenter for Innovation & Precision Dentistry, School of Dental Medicine and School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA.
Una O'DohertyDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
Alfred L GarfallDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Dan T VoglDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Edward A StadtmauerDepartment of Medicine, University of Pennsylvania, Philadelphia, PA.
Ping WangDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
University of Pennsylvania · USCenter for Innovation · USTranslational Therapeutics (United States) · US

Funding

Development of a Point-of-Care Volumetric Bar-Chart Chip for Drug QuantitationR01DA035868 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI QIN, LIDONG, WANG, PING · 2013 to 2020
$4.3M
SCH: Monitoring safety and adherence of pain management though remote opioidR01EB029363 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI LEE, INSUP, WANG, PING · 2019 to 2022
$902k
NIBIB NIH HHS R01 EB029363NIDA NIH HHS R01 DA035868
6 · The paper itself

Abstract

Background: Little is known about the dynamics of SARS-CoV-2 antigen burden in respiratory samples in different patient populations at different stages of infection. Current rapid antigen tests cannot quantitate and track antigen dynamics with high sensitivity and specificity in respiratory samples. Methods: We developed and validated an ultra-sensitive SARS-CoV-2 antigen assay with smartphone readout using the Microbubbling Digital Assay previously developed by our group, which is a platform that enables highly sensitive detection and quantitation of protein biomarkers. A computer vision-based algorithm was developed for microbubble smartphone image recognition and quantitation. A machine learning-based classifier was developed to classify the smartphone images based on detected microbubbles. Using this assay, we tracked antigen dynamics in serial swab samples from COVID patients hospitalized in ICU and immunocompromised COVID patients. Results: The limit of detection (LOD) of the Microbubbling SARS-CoV-2 Antigen Assay was 0.5 pg/mL (10.6 fM) recombinant nucleocapsid (N) antigen or 4000 copies/mL inactivated SARS-CoV-2 virus in nasopharyngeal (NP) swabs, comparable to many rRT-PCR methods. The assay had high analytical specificity towards SARS-CoV-2. Compared to EUA-approved rRT-PCR methods, the Microbubbling Antigen Assay demonstrated a positive percent agreement (PPA) of 97% (95% confidence interval (CI), 92-99%) in symptomatic individuals within 7 days of symptom onset and positive SARS-CoV-2 nucleic acid results, and a negative percent agreement (NPA) of 97% (95% CI, 94-100%) in symptomatic and asymptomatic individuals with negative nucleic acid results. Antigen positivity rate in NP swabs gradually decreased as days-after-symptom-onset increased, despite persistent nucleic acid positivity of the same samples. The computer vision and machine learning-based automatic microbubble image classifier could accurately identify positives and negatives, based on microbubble counts and sizes. Total microbubble volume, a potential marker of antigen burden, correlated inversely with Ct values and days-after-symptom-onset. Antigen was detected for longer periods of time in immunocompromised patients with hematologic malignancies, compared to immunocompetent individuals. Simultaneous detectable antigens and nucleic acids may indicate the presence of replicating viruses in patients with persistent infections. Conclusions: The Microbubbling SARS-CoV-2 Antigen Assay enables sensitive and specific detection of acute infections, and quantitation and tracking of antigen dynamics in different patient populations at various stages of infection. With smartphone compatibility and automated image processing, the assay is well-positioned to be adapted for point-of-care diagnosis and to explore the clinical implications of antigen dynamics in future studies.

Identifiers

PMID33791710
PMCPMC8010739
OpenAlexW3137912180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.